Trial Details

Not Recruiting
Basic Information
Clinical ID c3027
Identifier ISRCTN15765858
Trial Title Urinary excretion levels of MMX-mesalazine in healthy volunteers: a non-randomised study
Trial URL Visit Original Page
Study Information
Study Results

No results available

Conditions Urinary excretion MMX-mesalazine, pharmacokinetics. Now studied in healthy volunteers. To be used in inflammatory bowel disease (IBD) patients in the future. Digestive System
Interventions All 25 healthy adult volunteers used MMX-mesalazine ( 2400 mg once daily (OD) (days 1-4), followed by 1200 mg twice daily (BID) (days 8-11), separated by a drug-free interval of 3 days (days 5-7). Daily morning urine spot samples were collected prior to the morning dose.
Participant Information
Sponsor Radboud University Nijmegen Medical Centre
City -
Country/Region Netherlands
Enrollment Criteria
Sex Requirement ALL
Age Requirement -
Study Design
Study Type Interventional
Phase Not Available
Time Information
Start Date 2025-04-24
Primary Completion Date -
Completion Date -